By Ramsey Baghdadi
As the November 17 Medicare Evidence Development & Coverage Advisory Committee meeting for Dendreon's prostate cancer cell-based immunotherapy Provenge approached, here is how one person familiar with the situation described...
Dendreon vs. CMS: "Full Coverage" or the CED Solution?
A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?